Masjedizadeh Abdolrahim, Zaeemzadeh Narjes, Mard Seyyed Ali, Vanani Ghazal Salehi
Research Center for Infectious Diseases of Digestive System, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Research Center for Infectious Diseases of Digestive System, Departement of Pharmacology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Prz Gastroenterol. 2015;10(2):94-9. doi: 10.5114/pg.2015.49001. Epub 2015 Feb 10.
Helicobacter pylori (H. pylori) is the common cause of many gastrointestinal diseases, especially peptic ulcer. Therefore, a successful treatment of this infection decreases the financial burden on health systems.
Different combinations of antibiotics are used for the eradication of this bacterium worldwide. The goal of this study is to compare the efficacy of four different protocols used for this purpose in Ahvaz.
A total number of 400 patients with H. pylori infection were randomly divided into four groups (100 in each): (1) OAC: omeprazole (20 mg/b.i.d.), amoxicillin (1000 mg/b.i.d.), clarithromycin (500 mg/b.i.d.) for 10 days. (2) OCF: omeprazole (20 mg/b.i.d.), ciprofloxacin (500 mg/b.i.d.), furazolidone (100 mg/b.i.d.) for 10 days. (3) OBAM: omeprazole (20 mg/b.i.d.), bismuth subcitrate (240 mg/b.i.d.), amoxicillin (1000 mg/b.i.d.), metronidazol (500 mg/b.i.d.) for 14 days. (4) OBTM: omeprazole (20 mg/b.i.d.), bismuth subcitrate (240 mg/b.i.d.), tetracycline (500 mg/b.i.d.), metronidazol (500 mg/b.i.d.) for 14 days. At the end the viability of the bacterium was assessed by C(14) urea breath test.
The rate of H. pylori eradication was 92%, 59%, 73%, and 76% in OAC, OCF, OBAM, and OBTM groups, respectively (based on intention to treat analysis). The eradication rate was 93.9%, 62.1%, 77.7%, and 84.4% in OAC, OCF, OBAM, and OBTM groups, respectively (based on per protocol analysis). There was a statistically significant increase in eradication rate in the OAC group in comparison with the others (p < 0.001).
Standard triple therapy (omeprazole, amoxicillin, clarithromycin) remains the most effective regimen for H. pylori eradication in Ahvaz.
幽门螺杆菌(H. pylori)是许多胃肠道疾病的常见病因,尤其是消化性溃疡。因此,成功治疗这种感染可减轻卫生系统的经济负担。
在全球范围内,不同的抗生素组合用于根除这种细菌。本研究的目的是比较在阿瓦士为此目的使用的四种不同方案的疗效。
总共400例幽门螺杆菌感染患者被随机分为四组(每组100例):(1)OAC组:奥美拉唑(20毫克/每日两次)、阿莫西林(1000毫克/每日两次)、克拉霉素(500毫克/每日两次),疗程10天。(2)OCF组:奥美拉唑(20毫克/每日两次)、环丙沙星(500毫克/每日两次)、呋喃唑酮(100毫克/每日两次),疗程10天。(3)OBAM组:奥美拉唑(20毫克/每日两次)、枸橼酸铋钾(240毫克/每日两次)、阿莫西林(1000毫克/每日两次)、甲硝唑(500毫克/每日两次),疗程14天。(4)OBTM组:奥美拉唑(20毫克/每日两次)、枸橼酸铋钾(240毫克/每日两次)、四环素(500毫克/每日两次)、甲硝唑(500毫克/每日两次),疗程14天。最后通过C(14)尿素呼气试验评估细菌的生存能力。
根据意向性分析,OAC、OCF、OBAM和OBTM组的幽门螺杆菌根除率分别为92%、59%、73%和76%。根据符合方案分析,OAC、OCF、OBAM和OBTM组的根除率分别为93.9%、62.1%、77.7%和84.4%。与其他组相比,OAC组的根除率有统计学显著提高(p < 0.001)。
标准三联疗法(奥美拉唑、阿莫西林、克拉霉素)仍然是阿瓦士根除幽门螺杆菌最有效的方案。